fezziwig2008's  Instablog

Send Message
Research Background- I only invest in areas of interest that are familiar.
  • The Next Roche-Halo Partnership- Antibiotics For Superbugs  2 comments
    Jun 27, 2014 8:41 AM

    There are 10 targets to go on the 2006 Roche- Halozyme Agreement-


    Research shows that the addition of Enhanze- rhupH20- to subcutaneously delivered antibiotics improves their Maximum Concentration and Duration, making them superior to antibiotics delivered through oral, Iv , or Subcut without rhupH20 routes. Roche has declared its entry into the race for treatment of MRSA and other superbugs. They have made 3 acquisitions in this effort this year. Given the difficulty in treating these virulent and adaptive pathogens, surely the advantage that rhupH20 offers will be utilized under the agreement in force with Halozyme.

    New $HALO App Antibiotics-Use of SC rhupH20 increased absorption capacity, increased the Concentration & added one hour to the duration vs SC & IV

    Basis for new Antibiotic Application- Safety & pharmacokinetics of subcutaneous ceftriaxone administered with or without rHuPH20 Curr Med Res Opin


    RhupH20 increases Antibiotic Max Concentration/Duration-allowing $RHHBY advantage over $CBST $CEMP $DRTX- Makes SC Antibiotics better than IV or po

    Subcut has compliance and ease of administration advantages- requiring less skilled labor and lower supervision/administration costs.

    "Subcut ceftriaxone admin seems to be preferred for fragile elderly patients independent of disease severity" http://www.ncbi.nlm.nih.gov/pubmed/?term=Subcutaneous+and+intravenous+ceftriaxone+administration+in+patients+more+than+75+years+of+age $HALO

    Roche Returns to Antibiotic Research as Superbug Threat Grows" Employing technology they used to fight Cancer- like rhupH20 SC


    Disclosure: The author is long HALO.

Back To fezziwig2008's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (2)
Track new comments
  • fezziwig2008
    , contributor
    Comments (153) | Send Message
    Author’s reply » Every advantage is required to battle hospital and nursing home based superbacteria. With a Roche-HALO deal in place and confirmatory research on Rocephin in the can- this concept is a natural.
    27 Jun 2014, 03:24 PM Reply Like
  • fezziwig2008
    , contributor
    Comments (153) | Send Message
    Author’s reply » The GAIN Act gives drug makers 5 extra years of market exclusivity for bringing to market a superbug therapy-a mini Orphan Drug designation. This is one major reason Roche has returned to antibiotics. They will use all tools at their disposal.
    19 Jul 2014, 04:46 AM Reply Like
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.